TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) has announced a conference call scheduled for Tuesday, August 6, 2024, at 8:30 AM ET to discuss the company's second quarter 2024 financial results and provide a business outlook for 2024. The call will be hosted by Michael S. Weiss, Chairman and CEO. Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside U.S.). A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days after the call. TG Therapeutics will release its financial results in a press release prior to the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TGTX declined 6.97%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to be held Tuesday, August 6, 2024, at 8:30 AM ET
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) hosting its Q2 2024 earnings call?
Who will be hosting TG Therapeutics' (TGTX) Q2 2024 earnings call?
How can investors participate in TG Therapeutics' (TGTX) Q2 2024 earnings call?
Where can investors find TG Therapeutics' (TGTX) Q2 2024 financial results?
